Effect of A/T/N imaging biomarkers on impaired odor identification in Alzheimer's disease by 류철형 et al.
1
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:11556  | https://doi.org/10.1038/s41598-020-68504-2
www.nature.com/scientificreports
Effect of A/T/N imaging biomarkers 
on impaired odor identification 
in Alzheimer’s disease
Min Seok Baek1,4, Hanna Cho1,4, Hye Sun Lee2, Jae Hoon Lee3, Young Hoon Ryu3 & 
Chul Hyoung Lyoo1*
Odor identification ability may serve as an important diagnostic biomarker in Alzheimer’s disease 
(AD). The aim of the study is to investigate the contribution of A/T/N neuroimaging biomarkers 
to impaired odor identification ability in the Alzheimer’s disease spectrum. In 127 participants, 
we compared A/T/N neuroimaging biomarkers between normosmia and hyposmia groups, and 
performed correlation analysis between the biomarkers and Cross-Cultural Smell Identification 
Test (CCSIT) scores. Additionally, path analysis for odor identification ability was performed using 
cognitive function as a mediator. In between-group comparison, individuals with hyposmia showed 
higher frequency of amyloid-β (Aβ) positivity, and lower neuropsychological test performance than 
those with normosmia. After correction for covariates including total cognition scores, there was no 
difference in the Aβ or tau burden between the normosmia and hyposmia groups, and no correlation 
between CCSIT scores and Aβ or tau burden. Meanwhile, cortical volumes in the lateral and medial 
temporal cortices were smaller in the hyposmia group and decreased with the worsening of CCSIT 
scores. Path analysis showed that only neurodegeneration had a direct effect on odor identification, 
while Aβ and tau burden contributed to odor identification with the mediation of cognition. In 
the Alzheimer’s disease spectrum, impaired odor identification ability may be attributable to 
neurodegeneration rather than the direct effect of Aβ or tau burden.
Odor identification ability is impaired in patients with Alzheimer’s disease (AD)1. A step-wise deterioration 
of odor identification ability with the advancement of cognitive status enabled discrimination of cognitively 
unimpaired individuals, mild cognitive impairment (MCI), and AD  patients2,3. Longitudinal studies on MCI 
patients also showed that poor odor identification ability was associated with cognitive  decline4,5, and thereby 
predicted conversion from MCI to  AD4,6. In postmortem studies, impaired antemortem odor identification 
ability was associated with the amyloid-β (Aβ) burden in the global  cortex7, and tau in the entorhinal cor-
tex and  hippocampus7,8, and was therefore helpful for predicting Aβ-positivity by in vivo positron emission 
tomography (PET)9,10. Additionally, impaired odor identification has been associated with the CSF biomarker 
for  neurodegeneration11 and volume atrophy in the medial temporal  cortex12,13 where tau pathology appears 
early in  AD14. However, in these A/T/N biomarkers, there is no information regarding which biomarker has the 
greatest effect on odor identification.
Olfactory function not only requires the physical activation of diverse olfactory receptor cells by chemi-
cal substances, but also includes adaptation process to provide sensitivity and amplification and inhibition to 
enhance the odor detection. Subsequently, olfactory information is transferred to the cerebral cortex to interact 
with emotional response and higher olfactory function such as odor  identification15,16. This process requires 
memory and naming functions, suggesting that cognitive impairment may directly affect the odor identification 
 ability17,18. Moreover, the brain regions related to the central olfactory pathway, such as the entorhinal cortex, 
amygdala, and hippocampus overlap with the regions most vulnerable to pathological changes in  AD19–21. There-
fore, it remains unclear whether AD pathology directly effects odor identification ability, or if it is mediated by 
cognitive dysfunction.
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In this study, we sought to investigate the relationship between odor identification ability and each A/T/N 
imaging biomarker. We additionally investigated whether cognitive dysfunction mediates the association between 
the biomarkers and impaired odor identification.
Results
Demographic characteristics. Detailed demographic characteristics of the study participants are sum-
marized in Table 1. Out of 127 participants, 72 participants showed normosmia and 55 showed hyposmia. The 
ApoE ε4 allele was more frequently found in the hyposmia group than the normosmia group. The hyposmia 
group was older and more likely to be Aβ-positive and dementia status than the normosmia group. Likewise, 
the hyposmia group showed worse global cognition as measured by MMSE score, CDR-SB, and total cognition 
score and worse cognitive domain functions including memory, language and related, visuospatial, and frontal/
executive functions.
In 59 Aβ-positive individuals, the hyposmia group was still older than the normosmia group, and showed 
worse global cognition and worse cognitive domain functions including language and related and frontal/execu-
tive functions. In addition, Cross-Cultural Smell Identification Test (CCSIT) scores correlated with total cogni-
tion scores (Fig. 1).
Comparison of A/T/N biomarkers between the normosmia and hyposmia groups. After cor-
rection for age, sex, years of education, presence of ApoE ε4, and total cognition score in all participants, the 
normosmia and hyposmia group did not show difference in the regional Aβ and tau burden. Meanwhile, the 
hyposmia group exhibited smaller volumes in the entorhinal cortex (Fig. 2a). In Aβ-positive individuals, the 
hyposmia group showed smaller volumes in the global cortex, superior and middle temporal, and entorhinal 
cortices, amygdala, and hippocampus (Fig. 2b).
Association between odor identification ability and A/T/N biomarkers. In contrast to Aβ and tau 
burden which did not correlate with CCSIT score, low CCSIT score was associated with the atrophy in the global 
cortex, lateral temporal, entorhinal, and parahippocampal cortices, and amygdala (Fig. 3a). In Aβ-positive indi-
viduals, low CCSIT score was related with the atrophy in the global cortex, inferior parietal, superior and middle 
temporal, and entorhinal cortices, amygdala, and hippocampus (Fig. 3b).
Because there was a correlation between the CCSIT and total cognition scores, we primarily included total 
cognition score as a covariate to investigate the pure effect of tau and Aβ burden on deterioration of odor 
identification function independent of worsening global cognition. However, because the tau and Aβ burden 
also increase with the worsening of cognition, there remains a concern that the correlation between the CCSIT 
scores and tau and Aβ burden might not be detected. Therefore, we repeated the analysis without controlling for 
total cognition score and found that CCSIT score correlated with Aβ and tau burden in the widespread cortical 
regions in all participants (see Supplementary Fig. S1a) and with tau burden in the global cortex, frontal, parietal, 
occipital, and posterior cingulate cortices, and amygdala in Aβ-positive individuals (see Supplementary Fig. S1b).
Table 1.  Baseline demographic characteristics cognitive function between normosmia and hyposmia groups. 
Data are presented as mean ± SD. Bold values represent statistically significant P value of < 0.05. CCSIT 
Cross-Cultural Smell Identification Test, CU cognitively unimpaired, MCI mild cognitive impairment, DEM 
dementia, ApoE apolipoprotein E, Aβ+/− Aβ-positivity, MMSE Mini-Mental State Examination, CDR-SB 
Clinical Dementia Rating sum-of-boxes, n.a not applicable.
Aβ ± Aβ + 
Normosmia Hyposmia P value Normosmia Hyposmia P value
N 72 55 25 34
Sex (M:F) 21:51 22:33 0.159 8:17 12:22 0.792
Age (years) 67.2 ± 9.0 75.4 ± 8.7 < 0.001 70.7 ± 9.3 76.9 ± 8.0 0.008
Education (years) 11.0 ± 4.3 11.2 ± 5.2 0.797 10.8 ± 3.7 11.1 ± 5.4 0.840
CCSIT 9.6 ± 1.2 4.9 ± 2.1 < 0.001 9.3 ± 1.1 4.3 ± 2.2 < 0.001
ApoE ε4+ (%) 13 (18%) 20 (36%) 0.020 16 (64%) 18 (53%) 0.396
CU/MCI/DEM (%) 42/44/14% 18/35/47% < 0.001 12/56/32% 9/29/62% 0.073
Amyloid positivity 25 (35%) 34 (62%) 0.002 25 (100%) 34 (100%) n.a
Neuropsychological tests
 MMSE 26.8 ± 2.9 22.7 ± 5.1 < 0.001 25.7 ± 3.8 20.9 ± 5.1 < 0.001
 CDR-SB 1.1 ± 1.4 3.0 ± 2.1 < 0.001 2.0 ± 1.7 3.7 ± 2.0 0.005
 Total cognition score 153.7 ± 38.3 116.7 ± 47.6 0.045 128.6 ± 42.1 104.3 ± 39.9 0.033
 Memory 55.9 ± 22.1 36.3 ± 23.6 0.010 41.7 ± 21.7 29.9 ± 18.5 0.108
 Language and related 22.1 ± 3.8 19.0 ± 5.4 0.003 20.7 ± 4.7 17.7 ± 5.3 0.033
  Visuospatial 30.5 ± 6.6 26.4 ± 9.5 0.040 27.0 ± 9.5 25.4 ± 9.7 0.298
 Frontal/executive 35.4 ± 11.3 25.9 ± 13.1 0.005 29.5 ± 11.2 22.2 ± 11.0 0.028
 Attention 9.9 ± 2.1 9.2 ± 2.6 0.270 9.6 ± 2.3 9.0 ± 2.1 0.187
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Mediation of cognitive function between A/T/N neuroimaging biomarkers and odor identifica-
tion ability. Path analysis was used to investigate whether the effect of A/T/N biomarkers on odor identifica-
tion ability was directly or indirectly mediated by cognitive function. Volumes of the amygdala and entorhinal 
cortex showed direct effects on the CCSIT score, and an indirect effect mediated by total cognition score was also 
noted (Fig. 4c,d). In contrast to volume, regional Aβ and tau burden did not show direct effects on the CCSIT 
score in the regions that showed high significance in correlation analyses (Fig. 4a,b). The effect sizes of indirect 
effects mediated by total cognition score were relatively small for the regional cortical volumes, compared to the 
regional Aβ and tau burden.
Discussion
In this study, we found that the hyposmia group exhibited smaller volume in the entorhinal cortex than the nor-
mosmia group. In Aβ-positive individuals, the hyposmia group exhibited more prominent volume atrophy in the 
medial and lateral temporal cortices than the normosmia group. In addition, deterioration of odor identification 
ability correlated with the volume atrophy in the medial and lateral temporal cortices. Meanwhile, there were 
no group differences in Aβ or tau burden, which did not correlate with the odor identification ability. Finally, of 
the three imaging biomarkers, only regional volume was directly related to the odor identification ability, while 
Aβ and tau burden were indirectly related to odor identification ability with cognitive dysfunction as a mediator.
Previous PET imaging studies have shown a higher negative predictive value of odor identification ability on 
Aβ burden in the elderly, suggesting that individuals with preserved odor identification ability are less likely to 
have Aβ  deposit9,10. In contrast, another PET study showed a correlation between odor identification ability and 
regional Aβ burden in the posterior cingulate, temporoparietal, and lingual cortices in MCI and AD  patients22. 
In a postmortem study, antemortem odor identification ability was negatively correlated with the pathological 
Aβ  burden7. In contrast to these studies which did not control for the effect of cognitive function, our study 
demonstrated a lack of correlation between the burden and deterioration of odor identification ability, after con-
trolling for total cognition score. Likewise, there was an indirect effect of Aβ burden on the odor identification 
ability mediated by cognition in the path analysis. These results indicate that Aβ burden has little direct effect 
on the odor identification ability.
Olfactory information is transmitted from the olfactory bulb to the primary olfactory cortex encompassing 
the anterior olfactory nucleus, piriform cortex, anterior cortical nucleus of the amygdala, and entorhinal corti-
ces. The cortical regions such as insula, hippocampus, and hypothalamus have neuronal connections with the 
primary olfactory cortex for the processing of olfactory  information23. Neurofibrillary tangle (NFT) pathology 
is found in the olfactory bulbs of AD  patients8,24 and the spatial distribution of NFT pathology in the early stage 
Figure 1.  Correlation between the total cognition scores and CCSIT scores. Correlation analysis was performed 
after adjusting for age, sex, presence of ApoE ε4 and years of education in all 127 participants (a), and 59 
amyloid-β positive participants (b). Blue dots represent CU, green dots MCI patients, and red dots DEM. 
Abbreviations: Aβ+ /− = Aβ-positivity, SUVR = standardized uptake value ratio, CU = cognitively unimpaired; 
MCI = mild cognitive impairment; DEM = dementia, ApoE = apolipoprotein E, SR = Standardized residual, 
CCSIT = Cross-Cultural Smell Identification Test.
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Figure 2.  Comparison of 18F-florbetaben, 18F-flortaucipir SUVR and cortical volume between normosmia and 
hyposmia groups in all participants (a), and amyloid-β positive participants (b). Regional SUVR values were 
compared between the two groups after adjusting for age, sex, years of education, presence of ApoE ε4 and total 
cognition scores. For the comparison of regional cortical volumes between the two groups, total intracranial 
volume was added to the list of covariates. Data are presented as means (horizontal bars) and standard 
deviations (error bars) of normosmia (red) and hyposmia (blue) groups. P-values for the difference between 
two groups are expressed as − log10 P. P-values presented with red bars indicate the regions that survived 
correcting for region-wise multiple comparisons (false discovery rate-corrected P < 0.05), and blue dotted lines 
represent uncorrected P < 0.05. Abbreviations: Aβ+ /− = Aβ-positivity, SUVR = standardized uptake value ratio, 
A = 18F-florbetaben SUVR, T = 18F-flortaucipir SUVR, N = cortical volume.
5
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:11556  | https://doi.org/10.1038/s41598-020-68504-2
www.nature.com/scientificreports/
Figure 3.  Correlation of CCSIT score with 18F-florbetaben, 18F-flortaucipir SUVR and cortical volume 
in all participants (a), and amyloid-β positive participants (b). We used Pearson’s correlation between the 
standardized residuals of CCSIT scores and regional SUVR values obtained with multiple linear regression 
model after adjusting for age, sex, years of education, presence of ApoE ε4 and total cognition scores. A covariate 
of intracranial volume was additionally adjusted for cortical volume. Horizontal bars represent P-values as 
− log10 P. Red bars represent the regions that survived correction for region-wise multiple comparisons (false 
discovery rate-corrected P < 0.05), and blue dotted lines represent uncorrected P < 0.05. In the right side 
panel, brain regions showing highest significance in correlation with 18F-florbetaben, 18F-flortaucipir, and 
cortical volume are presented respectively. Blue dots represent CU participants, green dots represent MCI 
patients, and red dots represent DEM. Abbreviations: Aβ+ /− = Aβ-positivity, SUVR = standardized uptake 
value ratio, A = 18F-florbetaben SUVR, T = 18F-flortaucipir SUVR, N = cortical volume, SR = Standardized 
residual, CCSIT = Cross-Cultural Smell Identification Test, CU = cognitively unimpaired; MCI = mild cognitive 
impairment; DEM = dementia, ApoE = apolipoprotein E.
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of AD overlaps the key regions for olfactory information processing such as the entorhinal cortex, hippocampus, 
and  amygdala25. We therefore may expect a contribution of tau pathology to impaired olfactory function in AD. 
However, a CSF tau biomarker  study26, and postmortem studies, did not find a correlation between tau burden 
and deterioration of olfactory  function27,28. One postmortem study including cognitively unimpaired elderly 
and AD patients showed an association between odor identification ability and NFT pathology in the entorhinal 
cortex and  hippocampus7. However, this correlation might be driven by AD patients with high NFT burden 
and worse cognition, because the study did not for control cognitive function. In our study, tau burden in the 
widespread cerebral cortex correlated with the deterioration of odor identification score, without adjusting for 
cognitive function. However, this correlation disappeared after the inclusion of cognitive function in the list of 
covariates. Similar to the results for Aβ, we found an indirect effect of tau burden on odor identification ability 
mediated by cognition in the path analysis.
Atrophy in the primary olfactory cortex and hippocampus is consistently found in individuals with impaired 
olfactory function in cognitively  unimpaired9, amnestic  MCI12, and AD  groups29. In accordance with previous 
studies, we found that impaired odor identification ability was associated with volume atrophy in the medial and 
lateral temporal cortices even after controlling for cognitive function. In contrast to our expectation that AD 
pathology, especially tau burden, might explain the volume atrophy and impaired odor identification ability, we 
found no direct effect of Aβ or tau burden on odor identification. Therefore, impaired olfactory function in AD 
may be attributable to neurodegeneration in the regions related to olfactory processing rather than the Aβ or 
tau burden. However, we must consider the contribution of other types of pathologies in AD. Coexisting Lewy 
body-related pathology in up to 50% of AD patients is a potential  candidate30. Lewy body-related pathology 
in the olfactory bulb and amygdala, which receives the olfactory projection is reported as a potential cause of 
olfactory dysfunction in neurodegenerative  diseases27,28. Another potential candidate is TDP-43 pathology found 
in 30–70% of  AD31. TDP-43 preferentially accumulates in the medial temporal cortex and even in the olfactory 
bulb in AD, and may cause deterioration of odor identification  function32.
Figure 4.  Schematic diagram of the path analyses for effect of A/T/N imaging biomarkers on odor 
identification ability. Path analysis for odor identification ability was performed using 18F-florbetaben, 
18F-flortaucipir SUVR and cortical volume as predictors and the total cognition score as a mediator. In the 
upper part, total effects (direct effect + indirect effect) of the A/T/N imaging biomarkers on odor identification 
are shown. In (c, d), the lower side of the triangle represents the direct effects of the cortical volume on odor 
identification ability. Indirect effects of the A/T/N imaging biomarkers on odor identification ability are 
obtained by multiplying two β-coefficients between A/T/N imaging biomarkers and cognition, and between 
cognition and odor identification ability. Only significant β-coefficients are shown. **P < 0.001, *P < 0.05.
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Our study was limited first by a relatively small sample size. Additionally, we used a brief odor identification 
test, with only 12 items, instead of using the more complex University of Pennsylvania Smell Identification Test 
(UPSIT) with 40 items. Even though these two tests were cross-validated33, and the brief odor identification 
test is being widely used across studies, UPSIT may provide more precise cut-off for dichotomizing normosmia 
and hyposmia groups. In addition, we did not test for odor detection. Although this is highly correlated with 
odor identification  test1, additional information about the olfactory function at receptor level may enable more 
accurate localization of the origin of olfactory dysfunction in AD. Lastly, with the cross-sectional study design, 
we could not examine changes in biomarkers throughout disease progression.
In conclusion, we identified the effects of A/T/N imaging biomarkers of AD on the odor identification abil-
ity. While Aβ and tau burden may have an indirect effect on odor identification ability mediated by cognition, 
neurodegeneration in the cortical regions related to olfactory processes may have a direct effect on odor identifi-
cation in AD. Therefore, odor identification ability may be a useful biomarker for the neurodegeneration in AD.
Methods
Participants. For this study, we included 129 individuals who completed the Cross-Cultural Smell Identifi-
cation Test (CCSIT), neuropsychological test battery, genotyping for apolipoprotein E (ApoE), brain magnetic 
resonance (MR) imaging, and two PET scans (18F-florbetaben for Aβ and 18F-flortaucipir for tau) at the Memory 
Disorder Clinic in Gangnam Severance Hospital during the period from January, 2015 to September, 2018. All 
patients with dementia (DEM) first presented with memory impairment and were clinically diagnosed with 
probable AD, as proposed by the National Institute of Neurological and Communicative Disorders and Stroke 
and the Alzheimer Disease and Related Disorders  Association34. MCI patients were diagnosed according to the 
Petersen’s criteria based on their neuropsychological test  performances35. No patient showed clinical features 
atypical of AD. Cognitively unimpaired individuals were healthy volunteers fulfilling Christensen’s diagnostic 
 criteria36, and showing normal cognition in neuropsychological test. We excluded two participants who had 
a rhinological problem at the time of CCSIT or a history of rhinological surgery. Finally, 127 participants (40 
cognitively unimpaired, 51 MCI, and 36 DEM) were included in this study. This study was approved by the 
institutional review board of Gangnam Severance Hospital (Ref# 3-2014-0286) and written informed consent 
was obtained from all participants and/or their legal guardians. All research was performed in accordance with 
the relevant guidelines and regulations.
Olfactory assessment. Odor identification ability was assessed using the  CCSIT33. The CCSIT includes 12 
microencapsulated odorants attached to test cards. Participants were instructed to scratch, sniff, and select one 
of the 4 examples. The final score was calculated as the number of correct answers. Based on the resulting CCSIT 
scores, all participants were classified into either the normosmia (score ≥ 8) or hyposmia (score < 8) group, as 
previously  reported37.
Neuropsychological tests. All participants underwent the Seoul Neuropsychological Screening 
 Battery38,39. We calculated subdomain scores for memory, language and related, visuospatial, frontal/executive, 
and attention functions with the items in the battery using the method described in a previous  study38. Total 
cognition score was calculated as the sum of all subdomain scores. Mini-Mental State Examination (MMSE) 
and Clinical Dementia Rating sum-of-boxes (CDR-SB) scores were also assessed for global cognitive function.
Acquisition of PET and MR images. Using a Biograph mCT PET/CT scanner (Siemens Medical Solu-
tions, Malvern, PA, USA), we acquired PET images for 20 min at 80 min after the injection of 18F-flortaucipir, 
and at 90 min after the injection of 18F-florbetaben. The two PET scans were done in separate days. Computed 
tomography (CT) images were acquired for attenuation correction prior to the PET scan. Finally, 3D PET images 
were reconstructed in a 256 × 256 × 223 matrix with 1.591 × 1.591 × 1 mm voxel size using the ordered-subsets 
expectation maximization algorithm. Aβ-positivity was determined by the agreement of two nuclear medicine 
specialists using a validated visual assessment  method40,41. Axial T1-weighted brain MR images were acquired 
by 3.0 T MR scanner (Discovery MR750; GE Medical Systems, Milwaukee, WI, USA) with 3D-spoiled gradient-
recalled sequences (512 × 512 matrix with voxel spacing 0.43 × 0.43 × 1 mm voxel size).
Image processing steps. T1-weighted MR images were processed with FreeSurfer 5.3 (Massachusetts 
General Hospital, Harvard Medical School; https ://surfe r.nmr.mgh.harva rd.edu) software for creating partici-
pant-specific volume-of-interests (VOIs) mask images as described in our previous  study42. MR images were first 
resliced to FreeSurfer space (256 × 256 × 256 matrix with 1 mm isovoxel) 25 segmented into gray and white mat-
ter, and then 3D-surfaces for gray and white matter were reconstructed. Cortical regions were parcellated using 
curvature information, and subcortical regions were segmented with the probabilistic registration method. By 
merging anatomically-related regions, participant-specific composite VOI images for 20 cortical and subcortical 
regions were created. Voxel counts for each region were considered to be regional volume.
Statistical parametric mapping 12 (Wellcome Trust Centre for Neuroimaging, London, UK) and in-house 
software implemented in MATLAB R2015b (MathWorks, Natick, MA, USA) were used to process the PET 
images and measure the regional uptake values. PET images were coregistered to individual MR images within 
FreeSurfer space, and then partial volume effect (PVE) was corrected with the region-based voxel-wise method by 
using the participant-specific VOI  images43. PVE-corrected SUVR images were then created with the cerebellar 
crus median obtained by overlaying the template cerebellar crus VOI on the spatially normalized PET images. 
Finally, by overlaying the participant-specific composite VOI, we measured regional PVE-corrected SUVR values.
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Statistical analysis. SPSS 23 (IBM Corp., Armonk, NY, USA) was primarily used for the statistical analy-
sis. For between-group comparisons, two-sample t-tests, and chi-square tests were used for continuous and cat-
egorical demographic data, respectively. Using the general linear model, regional SUVR values were compared 
between the normosmia and hyposmia groups after adjusting for age, sex, years of education, presence of ApoE 
ε4, and total cognition score. For the comparison of regional cortical volumes between the two groups, total 
intracranial volume was added to the list of covariates. For the correlation analysis between CCSIT scores and 
regional SUVR values, we first obtained standardized residuals of CCSIT scores and regional SUVR values after 
adjusting for age, sex, years of education, presence of ApoE ε4, and total cognition score by using the multiple 
linear regression model. For correlation analysis between CCSIT scores and regional cortical volumes, we used 
total intracranial volume as additional covariate for obtaining the standardized residuals. Pearson’s correlation 
was then used to test for correlation between the standardized residuals of CCSIT scores and those of regional 
SUVR and cortical volume. We repeated all tests without controlling for total cognition score. Only the regions 
that survived after correcting for multiple comparisons with the Benjamini-Hochberg’s false-discovery rate 
(FDR) method were considered to be  significant44. To evaluate whether cognition mediates the effects of A/T/N 
imaging biomarkers on CCSIT scores, path analysis was performed using R Statistical Package (Version 3.6.1; 
Institute for Statistics and Mathematics, Vienna, Austria) using the regional SUVR and cortical volume as pre-
dictors and total cognition score as a mediator. Brain regions showing the highe significance for correlation were 
included in the analysis. Bootstrapping mediation analysis with 1,000 repetitions was used in pathway  analyses45.
Data availability
Data generated by this study are available from the corresponding author on reasonable request. The data are 
not publicly available due to privacy restriction.
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